cbdMD Statistics
Total Valuation
cbdMD has a market cap or net worth of $7.16 million. The enterprise value is $7.06 million.
Important Dates
The next estimated earnings date is Wednesday, December 17, 2025, after market close.
| Earnings Date | Dec 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
cbdMD has 8.91 million shares outstanding. The number of shares has increased by 510.60% in one year.
| Current Share Class | 8.91M |
| Shares Outstanding | 8.91M |
| Shares Change (YoY) | +510.60% |
| Shares Change (QoQ) | +642.97% |
| Owned by Insiders (%) | 1.74% |
| Owned by Institutions (%) | 7.32% |
| Float | 8.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.09 |
| Forward PS | 0.35 |
| PB Ratio | 1.17 |
| P/TBV Ratio | 1.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.16.
| Current Ratio | 1.56 |
| Quick Ratio | 0.57 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 0.51 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -33.13% and return on invested capital (ROIC) is -15.78%.
| Return on Equity (ROE) | -33.13% |
| Return on Assets (ROA) | -9.44% |
| Return on Invested Capital (ROIC) | -15.78% |
| Return on Capital Employed (ROCE) | -28.41% |
| Revenue Per Employee | $453,002 |
| Profits Per Employee | -$115,494 |
| Employee Count | 42 |
| Asset Turnover | 1.60 |
| Inventory Turnover | 2.28 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.45% in the last 52 weeks. The beta is 2.21, so cbdMD's price volatility has been higher than the market average.
| Beta (5Y) | 2.21 |
| 52-Week Price Change | -77.45% |
| 50-Day Moving Average | 0.94 |
| 200-Day Moving Average | 1.58 |
| Relative Strength Index (RSI) | 38.53 |
| Average Volume (20 Days) | 251,758 |
Short Selling Information
The latest short interest is 398,585, so 4.47% of the outstanding shares have been sold short.
| Short Interest | 398,585 |
| Short Previous Month | 86,928 |
| Short % of Shares Out | 4.47% |
| Short % of Float | 4.55% |
| Short Ratio (days to cover) | 0.04 |
Income Statement
In the last 12 months, cbdMD had revenue of $19.03 million and -$4.85 million in losses. Loss per share was -$2.41.
| Revenue | 19.03M |
| Gross Profit | 11.64M |
| Operating Income | -1.79M |
| Pretax Income | -1.51M |
| Net Income | -4.85M |
| EBITDA | -641,470 |
| EBIT | -1.79M |
| Loss Per Share | -$2.41 |
Full Income StatementBalance Sheet
The company has $1.06 million in cash and $962,738 in debt, giving a net cash position of $96,821 or $0.01 per share.
| Cash & Cash Equivalents | 1.06M |
| Total Debt | 962,738 |
| Net Cash | 96,821 |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | 6.11M |
| Book Value Per Share | 0.69 |
| Working Capital | 2.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.04 million and capital expenditures -$191,368, giving a free cash flow of -$1.24 million.
| Operating Cash Flow | -1.04M |
| Capital Expenditures | -191,368 |
| Free Cash Flow | -1.24M |
| FCF Per Share | -$0.14 |
Full Cash Flow StatementMargins
Gross margin is 61.20%, with operating and profit margins of -9.43% and -7.96%.
| Gross Margin | 61.20% |
| Operating Margin | -9.43% |
| Pretax Margin | -7.96% |
| Profit Margin | -7.96% |
| EBITDA Margin | -3.37% |
| EBIT Margin | -9.43% |
| FCF Margin | n/a |
Dividends & Yields
cbdMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -510.60% |
| Shareholder Yield | -510.60% |
| Earnings Yield | -67.78% |
| FCF Yield | -17.26% |
Analyst Forecast
The average price target for cbdMD is $2.00, which is 149.07% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.00 |
| Price Target Difference | 149.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 7, 2025. It was a reverse split with a ratio of 1:8.
| Last Split Date | May 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
cbdMD has an Altman Z-Score of -23.29 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -23.29 |
| Piotroski F-Score | 3 |
